US EditionPublished • loading... • Updated
GSK to Buy Canada's 35Pharma for $950 Million
GSK is acquiring 35Pharma for $950 million to expand its pulmonary hypertension pipeline with HS235, targeting a market expected to reach $18 billion by 2032, officials said.
- GSK will pay $950 million to acquire 35Pharma for all its equity, including investigational assets HS235 and ozureprubart, announced in Montreal on Feb. 25, 2026.
- Amid limited treatment options for PH, GSK's pipeline push aims to strengthen respiratory, immunology & inflammation efforts to accelerate pulmonary hypertension therapies, GSK said.
- HS235 has completed phase 1 healthy‑volunteer trials and is soon entering studies in Pulmonary Arterial Hypertension and PH due to HFpEF, with reduced BMP9 and BMP10 binding to lower bleeding risks.
- GSK will lead global development, regulatory filings and commercialization responsibilities, with the transaction subject to filings under the Hart‑Scott‑Rodino Act, the Competition Act and the Investment Canada Act.
- The deal reflects the growing importance of activin signalling inhibitors, with the global PH therapies market forecast at $18 billion by 2032, and MSD's Winrevair sold $1.4 billion last year.
Insights by Ground AI
16 Articles
16 Articles
Coverage Details
Total News Sources16
Leaning Left2Leaning Right1Center7Last UpdatedBias Distribution70% Center
Bias Distribution
- 70% of the sources are Center
70% Center
L 20%
C 70%
Factuality
To view factuality data please Upgrade to Premium
